SCHEMBL1340416

SCHEMBL1340416

Cn1nccc1-c1ccc2c(c1)c1cc(-c3ccc(Cl)cc3Cl)c(=O)n(C)c1n2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ MAPT P10636 1/20 0.38
▸ CNR1 P21554 7/20 0.37
▸ CNR2 P34972 7/20 0.37
▸ HSD11B1 P28845 2/20 0.36
▸ GRM7 Q14831 1/20 0.36
▸ F2RL3 Q96RI0 1/20 0.35
▸ TNKS O95271 1/20 0.35
▸ HAVCR2 Q8TDQ0 1/20 0.35
▸ DRD2 P14416 2/20 0.35
▸ EGFR P00533 1/20 0.35
▸ ALOX5 P09917 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ GABRA1 P14867 1/20 0.35
▸ ADRA2C P18825 1/20 0.35
▸ MAPK3 P27361 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339397 0.89 MARS1 (0.39) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL1338705 0.88 MARS1 (0.42) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL1336974 0.86 CNR1 (0.38) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL1336927 0.84 PIK3CD (0.36) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL1339131 0.83 NOTUM (0.39) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL1338764 0.82 BRD4 (0.41) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL1339072 0.81 CNR1 (0.38) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL1338074 0.81 L3MBTL1 (0.40) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL1337210 0.80 KDM4E (0.37) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL1339274 0.80 KDM4E (0.40) ALDH1A1KDM4EGAAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 ALDH1A1 283/4885KDM4E 1908/4885GAA 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback